Global Hospital Infection Therapeutics Market Outlook 2016: Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs

Latest industry research report on Hospital acquired infections (HAIs) are one of the leading cause of death across the globe. They are also referred to as nosocomial infections or Healthcare-associated Infections. According to Centers for Disease Control and Prevention (CDC), 1 out of every 25 hospital admitted patient gets contracted with HAIs. Moreover, in the U.S., in 2011, around 75,000 hospitalized patients died from HAIs. The global hospital acquired therapeutics market has observed a significant growth owing to rising number of hospital admitted patients and improved diagnostics capable of differentiating different strains of microbes. Complacency among healthcare providers and poor maintenance of hygiene are the two major preventable causes leading to HAIs.

The global market is facing significant challenges such as growing antimicrobial resistance among certain strains of bacteria eg. Methicillin-Resistant Staphylococcus Aureus (MRSA). The major drivers of global hospital infection therapeutics market are the rising number of hospital admitted patients, poor infrastructure, understaffing and insufficient hospital equipment, overcrowding and lack of knowledge about blood transfusion safety measures, and rising geriatric population. However, stringent regulatory requirement, high cost of treatment and lack of transparent reimbursement scenario, are likely to hinder the market growth.

Access Full Report:
http://www.intenseresearch.com/market-analysis/world-hospital-infection-therapeutics-market-opportunities-and-forecasts.html

The global hospital infection therapeutics market is segmented on the basis of drug type, application, and geography. On the basis of drug type, the market is segmented into Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs and Others. According to application, the global market is segmented into, Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders and Other Hospital Infections. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. New drug approval and acquisitions are key strategies adopted by the top industry players.

For instance FDA approved a new drug named Oritavancin, an intravenous antibiotic, for the treatment of drug-resistant bacteria, including MRSA. Merck & Co. has acquired Cubist Pharmaceuticals, a company with late-stage pipeline focusing on healthcare-acquired bacterial infections. The companies profiled in the report include, Sanofi S.A., GlaxoSmithKline plc, AstraZeneca plc, Merck & Co., Inc., Pfizer, Inc, Actavis plc, Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company and Cubist Pharmaceuticals, Inc.

Request a Brochure of This Report, here: http://bit.ly/2cin5ex

About Intense Research

Intense Research provides a range of marketing and business research solutions designed for our client’s specific needs based on our expert resources. The business scopes of Intense Research cover more than 30 industries includsing energy, new materials, transportation, daily consumer goods, chemicals, etc. We provide our clients with one-stop solution for all the research requirements.

Contact Us:

Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442,
United States
Tel: +1-386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 1-855-465-4651
Email: sales@intenseresearch.com
Web: http://www.intenseresearch.com/

This release was published on openPR.